Top Markets
#1 ORDI ORDI +105.28%
#2 pippin pippin +48.89%
#3 tomiNet tomiNet +42.76%
#4 SATS (Ordinals) SATS (Ordinals) +41.44%
#5 1000SATS (Ordinals) 1000SATS (Ordinals) +40.63%
#6 Axelar Axelar +28.30%
#7 Bio Protocol Bio Protocol +27.90%
#8 Swarms Swarms +26.30%
#9 Drift Protocol Drift Protocol +25.62%
#10 MemeCore MemeCore +24.82%
Coin of the day
ORDI ORDI
Pengaturan
Bahasa
BAHASA INDONESIA
Mata uang
USD
Tema
Neovacs S.A. Neovacs S.A.

Neovacs S.A.

ALNEV
Peringkat dalam Saham #21228
Neovacs S.A., a biotechnology company, focuses on the development of... Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
Harga Saham
$0.00047446
Kapitalisasi Pasar
$82.80
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
-98.16%
Negara
FR
Perdagangan Neovacs S.A. (ALNEV)

Kategori

Healthcare
Laba untuk Neovacs S.A. (ALNEV)
Laba pada Dec 2024 TTM: $-35.33M
Menurut laporan keuangan terbaru dari Neovacs S.A., laba saat ini perusahaan adalah $-35.33M. Pada tahun 2023, perusahaan memperoleh laba sebesar $-10.63M, penurunan dibandingkan dengan laba tahun 2022 sebesar $-4.66M. Laba yang ditampilkan di halaman ini adalah laba sebelum bunga dan pajak, atau disebut juga EBIT.
Riwayat laba untuk Neovacs S.A. dari 2007 hingga 2026
Laba pada akhir setiap tahun
Tahun Laba Mengubah
2026 (TTM) $-35.33M 0.00%
2024 $-35.33M 232.17%
2023 $-10.63M 128.13%
2022 $-4.66M -67.15%
2021 $-14.19M 74.31%
2020 $-8.14M -22.00%
2019 $-10.44M -33.00%
2018 $-15.58M -31.17%
2017 $-22.63M 24.13%
2016 $-18.23M 131.65%
2015 $-7.87M -33.75%
2014 $-11.88M 7.75%
2013 $-11.03M 0.62%
2012 $-10.96M -12.83%
2011 $-12.57M -8.71%
2010 $-13.77M 14.01%
2009 $-12.08M 72.06%
2008 $-7.02M -9.80%
2007 $-7.78M 0.00%
Laba untuk perusahaan serupa atau pesaing
Perusahaan Laba Perbedaan Laba Negara
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
$20.51B -58,146.44%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$4.64B -13,244.00%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
$5.23B -14,907.10%
US
UCB SA UCB SA
UCB SA
UCB.BR
$2.14B -6,151.40%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.45B -4,207.73%
NL